Dr. Ying Huang

K2 Therapeutics (K2), a biotechnology company focused on advancing innovative therapies with global potential, has appointed Dr. Ying Huang as Chief Executive Officer. 

The company was founded by MPM BioImpact in 2024 with $50 million in seed financing.

K2 is pursuing a biotechnology model that combines global asset sourcing with experienced drug development leadership to identify and advance promising first-in-class and best-in-class therapeutic candidates. The seed financing has supported the expansion of the company’s portfolio and the advancement of assets sourced from markets worldwide.

Dr. Huang brings more than two decades of experience across biotechnology research and development, corporate strategy, capital markets and executive leadership.

Most recently, he served as Chief Executive Officer and a member of the Board of Directors at Legend Biotech, where he helped lead the global development and commercialization of cell therapies, including CARVYKTI®. Under his leadership, CARVYKTI became one of the early commercially successful drug launches from China into the U.S., generating annual sales of more than $2 billion.

Dr. Huang also oversaw Legend Biotech’s transformation into a fully integrated global biopharmaceutical company with more than 3,000 employees across research and development, GMP manufacturing and commercial operations.

Before joining Legend Biotech, Dr. Huang served as a biotechnology equity research analyst and Head of Biotechnology Equity Research at Bank of America Merrill Lynch. He began his career in pharmaceutical research and development.

Dr. Huang holds a Ph.D. in Bio-organic Chemistry from Columbia University. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and attended Columbia Business School.

His appointment provides K2 Therapeutics with experienced leadership as the company expands its globally sourced portfolio and advances potential first-in-class and best-in-class therapies.